Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

1.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.

Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.

PMID:
24950985
[PubMed - in process]
2.

Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges.

Ledermann JA, Ray-Coquard I.

Am Soc Clin Oncol Educ Book. 2014:e282-6. doi: 10.14694/EdBook_AM.2014.34.e282.

PMID:
24857114
[PubMed - in process]
Free Article
3.

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I.

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20. No abstract available.

PMID:
24651409
[PubMed - in process]
4.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.

PMID:
24637997
[PubMed - indexed for MEDLINE]
5.

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R.

Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21.

PMID:
24563479
[PubMed - in process]
6.

[To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhône-Alpes region].

Fayet Y, Chasles V, Ducimetière F, Collard O, Berger C, Meeus P, Ranchère-Vince D, Thiesse P, Sunyach MP, Marec-Bérard P, Poncet L, Cousin P, Blay JY, Ray-Coquard I.

Bull Cancer. 2014 Feb;101(2):127-36. doi: 10.1684/bdc.2014.1891. French.

PMID:
24556026
[PubMed - indexed for MEDLINE]
7.

Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

Toulmonde M, Bonvalot S, Ray-Coquard I, Stoeckle E, Riou O, Isambert N, Bompas E, Penel N, Delcambre-Lair C, Saada E, Lecesne A, Le Péchoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchère-Vince D, Neuville A, Italiano A; French Sarcoma Group.

Ann Oncol. 2014 Mar;25(3):730-4. doi: 10.1093/annonc/mdt576. Epub 2014 Feb 3.

PMID:
24496921
[PubMed - in process]
8.

The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?

Blay JY, Derbel O, Ray-Coquard I.

Pathology. 2014 Feb;46(2):121-5. doi: 10.1097/PAT.0000000000000052.

PMID:
24378393
[PubMed - in process]
9.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.

J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23.

PMID:
24366937
[PubMed - indexed for MEDLINE]
10.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

Poveda A, Ray-Coquard I, Romero I, Lopez-Guerrero JA, Colombo N.

Cancer Treat Rev. 2014 Apr;40(3):366-75. doi: 10.1016/j.ctrv.2013.08.001. Epub 2013 Aug 8. Review.

PMID:
24296108
[PubMed - indexed for MEDLINE]
Free Article
11.

Biology of ovarian cancer and trabectedin mechanism of action.

Ray-Coquard I.

Future Oncol. 2013 Dec;9(12 Suppl):11-7. doi: 10.2217/fon.13.199. Review.

PMID:
24195525
[PubMed - indexed for MEDLINE]
12.

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, Robin YM, Bay JO, Piperno-Neumann S, Blay JY, Fournier C.

Target Oncol. 2013 Nov 12. [Epub ahead of print]

PMID:
24218035
[PubMed - as supplied by publisher]
13.

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.

Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P.

Eur J Cancer. 2014 Jan;50(2):388-96. doi: 10.1016/j.ejca.2013.10.002. Epub 2013 Nov 8.

PMID:
24215845
[PubMed - indexed for MEDLINE]
14.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.

Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Laurraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A.

Gynecol Oncol. 2014 Jan;132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013. Epub 2013 Oct 22.

PMID:
24157616
[PubMed - indexed for MEDLINE]
15.

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.

Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Bui-Nguyen B, Blay JY, Tresch-Bruneel E, Fournier C, Clisant S, Amela EY, Cassier PA, Molimard M, Penel N.

Br J Cancer. 2013 Nov 12;109(10):2574-8. doi: 10.1038/bjc.2013.648. Epub 2013 Oct 22.

PMID:
24149182
[PubMed - indexed for MEDLINE]
16.

Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group.

Isambert N, Ray-Coquard I, Italiano A, Rios M, Kerbrat P, Gauthier M, Blouet A, Chaigneau L, Duffaud F, Piperno-Neumann S, Kurtz JE, Girard N, Collard O, Bompas E, Penel N, Bay JO, Guillemet C, Collin F, Blay JY, Le Cesne A, Thariat J.

Eur J Cancer. 2014 Jan;50(1):128-36. doi: 10.1016/j.ejca.2013.09.012. Epub 2013 Oct 14.

PMID:
24135684
[PubMed - indexed for MEDLINE]
17.

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.

Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, Matei D, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR.

Cancer. 2014 Feb 1;120(3):335-43. doi: 10.1002/cncr.28406. Epub 2013 Oct 11.

PMID:
24127346
[PubMed - indexed for MEDLINE]
18.

Advanced chondrosarcomas: role of chemotherapy and survival.

Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz JE, Collard O, Bertucci F, Bompas E, Le Cesne A, Maki RG, Ray Coquard I, Blay JY.

Ann Oncol. 2013 Nov;24(11):2916-22. doi: 10.1093/annonc/mdt374. Epub 2013 Oct 7.

PMID:
24099780
[PubMed - indexed for MEDLINE]
19.

Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.

Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I.

Crit Rev Oncol Hematol. 2014 Feb;89(2):207-16. doi: 10.1016/j.critrevonc.2013.08.017. Epub 2013 Sep 8.

PMID:
24071502
[PubMed - in process]
20.

[Care networks in oncology, an evidence for all?].

Ray-Coquard I, Ducimetière F, Farsi F.

Bull Cancer. 2013 Jul-Aug;100(7-8):650-4. French. No abstract available.

PMID:
24063023
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk